RECRUITING

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Talk to us

Conditions

Renal Cell CarcinomaStereotactic Body Radiation TherapySBRTRCC

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Official Title

Prospective Phase II Study of Stereotactic Body Proton Therapy for Treatment of PrimAry Renal Cell Carcinoma (SPARE)

Quick Facts

Study Start:2025-02-25
Study Completion:2030-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06376669

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age ≥ 18 years
  2. 2. Biopsy proven renal cell carcinoma.
  3. 3. No clinical or radiographic evidence of metastatic disease.
  4. 4. Not a candidate for surgical treatment or local ablative procedures.
  5. 5. Subjects are able to undergo either an MRI or administration of contrast agent for CT.
  1. 1. Prior history of radiation treatment with overlapping fields.
  2. 2. Patients with proven metastatic disease.
  3. 3. Female subjects who are pregnant or planning to become pregnant during the treatment.

Contacts and Locations

Study Contact

Sherif Shaaban
CONTACT
202-919-2523
sshaaba1@jhmi.edu
Ryan Manuel
CONTACT
410-955-4261
rmanuel5@jhmi.edu

Principal Investigator

Sherif Shaaban, MD
PRINCIPAL_INVESTIGATOR
Johns Hopkins University

Study Locations (Sites)

Sibley Memorial Hospital
Washington, District of Columbia, 20016
United States

Collaborators and Investigators

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

  • Sherif Shaaban, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-25
Study Completion Date2030-08

Study Record Updates

Study Start Date2025-02-25
Study Completion Date2030-08

Terms related to this study

Keywords Provided by Researchers

  • Stereotactic Body Radiation Therapy
  • SBRT
  • RCC

Additional Relevant MeSH Terms

  • Renal Cell Carcinoma